Ritu Lal

Ritu Lal

Company: Gen1E Lifesciences

Job title: Chief Executive Officer

Seminars:

Unlocking Multiple Mechanisms of Action Using a Unique AI/ML Platform with Novel Immunomodulators for ARDS Patients 8:45 am

Highlighting the lead compound is Phase 2 ready for ARDS patients (including COVID-ARDS) having completed Phase 1 Using the unique AI/ML platform to develop 21 next generation p38 alpha/MK2 novel immunomodulatorsRead more

day: Day Two

Panel Discussion: Determining the Extent the Understandings Gained from Covid-19 ARDS Can Be Translated Into ARDS 2:55 pm

Read more

day: Day Two

Unlocking Multiple Mechanisms of Action Using a Unique AI/ML Platform with Novel Immunomodulators for ARDS Patients 8:50 am

Highlighting the lead compound is Phase 2 ready for ARDS patients (including COVID-ARDS) having completed Phase 1 Using the unique AI/ML platform to develop 21 next generation p38 alpha/MK2 novel immunomodulatorsRead more

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.